Background
RE-VERSE AD was a prospective cohort study (n=503) of patients on dabigatran requiring reversal for uncontrolled/life-threatening bleeding (Group A, n=301) or urgent surgery/procedure (Group B, n=202). Idarucizumab is a humanized Fab that binds dabigatran with ~350-fold greater affinity than dabigatran has for thrombin, rapidly neutralizing its anticoagulant effect.
Interventions and follow up
Regimen: Idarucizumab 5 g IV (administered as two 2.5 g infusions no more than 15 minutes apart) once.
Primary endpoint: Maximum percentage reversal of dabigatran effect within 4 hours (dTT or ECT).
mFollow up: 90 days
Primary endpoint: Maximum percentage reversal of dabigatran effect within 4 hours (dTT or ECT).
mFollow up: 90 days
Results
Maximum reversal of dabigatran effect: 100% (median; 98–100% by dTT and ECT) within minutes
Group A (bleeding) median time to hemostasis: 2.5 hours (excellent/good hemostasis ~68%)
Group B (urgent surgery) median time to procedure: 1.6 hours (92% normal intraoperative hemostasis)
Thrombotic events at 90 days: 6.3%
Death at 90 days: 13.5% (Group A), 12.6% (Group B)
Group A (bleeding) median time to hemostasis: 2.5 hours (excellent/good hemostasis ~68%)
Group B (urgent surgery) median time to procedure: 1.6 hours (92% normal intraoperative hemostasis)
Thrombotic events at 90 days: 6.3%
Death at 90 days: 13.5% (Group A), 12.6% (Group B)
Adverse events
Hypokalemia and delirium reported, likely related to underlying illness. Thrombotic events 6.3% at 90 days (DVT, PE, MI, stroke) — attributable to underlying thrombotic conditions and cessation of anticoagulation rather than the drug. No serious drug-related hypersensitivity. Re-elevation of dabigatran levels in ~14% at 12–24 hours (redistribution), warranting monitoring.
Conclusions
Idarucizumab achieved immediate, complete reversal of dabigatran anticoagulation in 100% of patients within minutes, with rapid hemostasis in bleeding patients and prompt ability to proceed with urgent procedures, establishing it as the specific antidote for dabigatran reversal.
Key Limitations
Non-randomized cohort — no control group; hemostatic efficacy assessment was adjudicated subjectively; 100% dabigatran reversal does not always translate to clinical hemostasis; thrombotic event rate reflects patient acuity; dabigatran redistribution can cause delayed re-elevation.
Clinical Context
Idarucizumab (Praxbind) was the first specific antidote for a DOAC, FDA-approved October 2015 for dabigatran reversal in life-threatening bleeding or urgent surgery. ACC/AHA and ACCP guidelines recommend idarucizumab as the specific reversal agent for dabigatran. For factor Xa inhibitors, andexanet alfa is the specific antidote; 4F-PCC is an alternative.